Prostate Specific Antigen Test Market By Type (Preliminary Tests, Confirmatory Tests); By Application (Prostate Cancer Screening, Prostate Cancer Monitoring); By End Use (Hospitals, Specialty Clinics, Diagnostic Centers); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Prostrate Specific Antigen Test Market size was valued at USD 4.63 Billion in 2024 and is anticipated to reach USD 11.23 Billion by 2032, at a CAGR of 11.7% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Prostrate Specific Antigen Test Market Size 2024
USD 4.63 Billion
Prostrate Specific Antigen Test Market, CAGR
11.7%
Prostrate Specific Antigen Test Market Size 2032
USD 11.23 Billion
Roche, Abbott Laboratories Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., GE HealthCare, Beckman Coulter, Inc., FUJIREBIO, Laboratory Corporation of America Holdings, Bayer AG, Abcam plc, Lomina AG, LynxDx, and AdvaCare Pharma are the leading players in the prostate-specific antigen test market, driving innovation and competitive growth. These companies focus on developing highly sensitive and reliable assays to support early detection and monitoring of prostate cancer. Strategic collaborations, research investments, and regional expansions strengthen their market presence. North America led the market in 2024 with a 38% share, followed by Europe at 29%, Asia Pacific at 22%, Latin America at 7%, and the Middle East and Africa at 4%. The region’s dominance is supported by advanced healthcare infrastructure, high awareness, and government-led screening programs, while emerging regions present significant growth opportunities due to rising healthcare investments and increasing patient awareness.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The prostate-specific antigen test market was valued at USD 4.63 Billion in 2024 and is projected to reach USD 11.23 Billion by 2032, growing at a CAGR of 11.7%.
Rising prostate cancer prevalence, government-led screening programs, and technological advancements in testing are key drivers supporting market growth.
The market is witnessing trends toward personalized medicine, point-of-care testing, and integration of molecular biomarkers with PSA tests for more precise diagnostics.
Competitive landscape is dominated by major players focusing on product innovation, strategic collaborations, and expanding regional presence to strengthen market share.
North America led with 38% market share, followed by Europe at 29%, Asia Pacific at 22%, Latin America at 7%, and Middle East & Africa at 4%; preliminary tests held the largest segment share in 2024.
Market Segmentation Analysis:
By Type
The prostate-specific antigen (PSA) test market by type is segmented into preliminary tests and confirmatory tests. Preliminary tests dominated the segment in 2024, holding over 58% market share. Their wide use as first-line screening tools in routine health check-ups and large-scale cancer awareness programs drives this dominance. High accessibility, lower cost, and simplicity make preliminary tests more widely adopted in both developed and emerging regions. Growing awareness about early cancer detection further strengthens demand for preliminary PSA tests, while confirmatory tests continue to gain traction for precise diagnostics in complex cases.
For instance, Abbott Laboratories’ ARCHITECT i2000SR immunoassay system can process up to 200 tests per hour, and is used for a variety of immunoassay tests, including PSA.
By Application
Based on application, the market is categorized into prostate cancer screening and prostate cancer monitoring. Prostate cancer screening accounted for the largest share at nearly 62% in 2024, fueled by rising awareness programs and government initiatives encouraging early diagnosis. Increasing prevalence of prostate cancer globally, particularly in aging male populations, has made screening a primary focus. The role of PSA tests as effective preventive tools contributes to their high adoption. In contrast, prostate cancer monitoring is gaining importance as personalized treatment and long-term patient management become more critical in oncology practices.
For instance, Roche Diagnostics’ Elecsys total PSA assay has a Limit of Quantitation (LoQ) of 0.014 ng/mL and a Limit of Detection (LoD) of 0.010 ng/mL
By End Use
In terms of end use, the market is divided into hospitals, specialty clinics, and diagnostic centers. Hospitals held the dominant position in 2024 with more than 45% share, supported by their advanced infrastructure, large patient base, and comprehensive diagnostic capabilities. The presence of multidisciplinary oncology units in hospitals ensures higher test volumes, particularly for newly diagnosed patients. Additionally, hospital-based reimbursement systems and integration of PSA testing in routine health screenings strengthen this dominance. Specialty clinics and diagnostic centers are expanding rapidly, driven by rising demand for quicker, cost-effective, and accessible prostate cancer testing options.
Key Growth Drivers
Rising Prostate Cancer Incidence
The increasing global burden of prostate cancer remains the most significant growth driver for the prostate-specific antigen (PSA) test market. Rising prevalence, especially among men aged 50 and above, has intensified demand for effective screening and monitoring. The World Health Organization reports prostate cancer as one of the most common cancers in men, pushing healthcare systems to adopt large-scale screening initiatives. Governments and healthcare organizations are also launching awareness campaigns, boosting the adoption of PSA tests as a critical tool for early diagnosis and better patient outcomes.
For instance, As a major provider of PSA tests in the U.S. for prostate cancer screening and monitoring, LabCorp reported that its total diagnostics volume, measured by requisitions, increased by 2.4% in the fourth quarter of 2023. However, this growth was primarily driven by acquisitions (2.1%) with only a minor contribution from organic volume (0.3%).
Technological Advancements in Testing
Advances in diagnostic technology, including ultrasensitive assays and point-of-care testing, are enhancing the accuracy and reliability of PSA tests. These innovations allow early-stage detection with reduced false positives and negatives, which builds confidence among clinicians and patients. Integration of biomarkers with advanced testing methods is further driving precision medicine approaches. Growing adoption of automated systems in laboratories reduces turnaround times, supporting efficiency in clinical workflows. Such advancements are encouraging higher uptake of PSA tests across hospitals, specialty clinics, and diagnostic centers worldwide.
For instance, Analyses using large datasets like the Behavioral Risk Factor Surveillance System (BRFSS) and the All of Us Research Program reveal that between 2018 and 2020, PSA testing in U.S. men aged 40 and older was influenced by factors including age, race, and screening guidelines. Specifically, testing rates continued to decline until 2020, a trend further affected by the COVID-19 pandemic.
Government Initiatives and Screening Programs
Government-led initiatives promoting cancer screening are accelerating PSA test adoption across developed and emerging regions. National screening policies, healthcare subsidies, and inclusion of PSA tests in preventive health packages are creating strong demand. Public health authorities are increasingly focused on reducing mortality rates by encouraging early detection, which directly supports market expansion. Insurance coverage and reimbursement programs in developed countries further enhance accessibility. This policy-driven support has positioned PSA testing as a standard diagnostic tool in oncology, ensuring steady market growth throughout the forecast period.
Key Trends and Opportunities
Shift Toward Personalized Medicine
The move toward personalized medicine is reshaping the PSA test market, opening opportunities for more tailored cancer diagnostics. Advanced tests now integrate genetic markers and molecular profiling with PSA levels, enabling improved risk stratification. This approach allows clinicians to design individualized treatment plans, reducing unnecessary biopsies and improving patient outcomes. Growing collaboration between diagnostic companies and biotech firms supports this trend, as innovation accelerates. The emphasis on precision oncology is expected to significantly boost adoption of PSA testing in both developed and emerging healthcare markets.
For instance, GLOBOCAN 2022 estimated 1,467,854 new prostate cancer cases and 397,430 deaths worldwide.
Expansion in Emerging Markets
Emerging economies present vast opportunities due to increasing healthcare expenditure, improving diagnostic infrastructure, and rising awareness of prostate health. Countries in Asia-Pacific and Latin America are witnessing rapid growth in demand for PSA testing, supported by government health campaigns and private investments in diagnostic facilities. Urbanization and aging male populations further drive this adoption. Additionally, international diagnostic companies are expanding their presence in these regions to tap into the growing patient pool. These factors position emerging markets as high-potential areas for sustained revenue growth in PSA testing.
For instance, According to a January 2025 analysis by Prostate Cancer UK, based on NHS data, prostate cancer diagnoses in England have surpassed breast cancer diagnoses for two consecutive years. The analysis found there were 50,751 diagnoses of prostate cancer in England in 2022, and this figure rose to 55,033 in 2023. This trend, which saw prostate cancer become the most common form of cancer diagnosed in England in 2023, is partly driven by increased awareness and targeted campaigns.
Key Challenges
False Positives and Overdiagnosis
One of the most pressing challenges in the PSA test market is the risk of false positives, which can lead to overdiagnosis and unnecessary treatments. Elevated PSA levels may result from benign conditions such as prostatitis or benign prostatic hyperplasia, creating diagnostic uncertainty. This often subjects patients to invasive biopsies, emotional distress, and increased healthcare costs. Such limitations have sparked debates about the test’s reliability and clinical value. Addressing these issues through advanced biomarkers and improved test specificity remains critical for building trust in PSA testing.
Limited Awareness in Low-Income Regions
Despite growing adoption globally, limited awareness in low-income regions continues to restrict market expansion. Inadequate healthcare infrastructure, lack of trained professionals, and minimal public education about prostate cancer screening hinder widespread adoption. Men in rural areas often remain unaware of the importance of early detection, resulting in late diagnoses and poor outcomes. Moreover, high test costs relative to local income levels reduce accessibility. Overcoming these barriers requires collaborative efforts between governments, NGOs, and diagnostic providers to expand outreach programs and strengthen healthcare delivery systems.
Regional Analysis
North America
North America led the prostate-specific antigen test market in 2024 with a 38% share. The region’s dominance stems from advanced healthcare infrastructure, widespread adoption of preventive screening, and strong government support for cancer awareness programs. High prevalence of prostate cancer among aging male populations further accelerates demand for PSA testing. Favorable reimbursement policies, well-established diagnostic facilities, and continuous technological innovations strengthen market growth. The presence of leading diagnostic companies and active research initiatives also contribute to the region’s leadership, making North America the largest and most mature market for PSA testing worldwide.
Europe
Europe accounted for nearly 29% of the global prostate-specific antigen test market in 2024. Strong healthcare systems, combined with national cancer screening programs, have increased PSA test adoption across the region. Countries such as Germany, the UK, and France are at the forefront of implementing advanced diagnostic practices. High awareness among patients and support from public health agencies are driving continuous growth. Technological advancements and investments in personalized medicine further enhance market expansion. Despite ongoing debates about overdiagnosis, Europe remains a key market supported by a large aging male population and well-integrated healthcare policies.
Asia Pacific
Asia Pacific captured around 22% share of the prostate-specific antigen test market in 2024, emerging as the fastest-growing region. Rising incidence of prostate cancer, growing healthcare investments, and government-led awareness programs are driving adoption. Countries such as China, India, and Japan are witnessing higher test volumes due to expanding diagnostic facilities and urbanization. Increasing affordability of healthcare services and improvements in infrastructure also support growth. International diagnostic companies are expanding in the region to tap into the large patient base. Asia Pacific’s rapid economic development positions it as a major contributor to future market expansion.
Latin America
Latin America held about 7% share of the prostate-specific antigen test market in 2024. Growth in this region is supported by rising healthcare awareness and increasing focus on early cancer detection. Brazil and Mexico are leading markets, benefiting from expanding private healthcare networks and government cancer screening initiatives. However, limited infrastructure in rural areas and high test costs remain challenges. The region is experiencing gradual improvement as international healthcare providers expand their presence and partnerships increase. Latin America is expected to show steady growth, driven by improving access to diagnostic technologies and rising patient awareness.
Middle East and Africa
The Middle East and Africa accounted for 4% of the global prostate-specific antigen test market in 2024. Market growth is constrained by limited healthcare infrastructure, low awareness of prostate cancer, and affordability issues. Despite these challenges, urban centers in Gulf countries such as the UAE and Saudi Arabia are witnessing rising adoption due to advanced medical facilities. Increasing investments in healthcare and government-led awareness programs are gradually improving access. Africa remains underpenetrated, though non-profit initiatives and international collaborations are expanding outreach. The region holds untapped potential as infrastructure development continues and diagnostic awareness rises.
Market Segmentations:
By Type:
Preliminary tests
Confirmatory tests
By Application:
Prostate cancer screening
Prostate cancer monitoring
By End Use:
Hospitals
Specialty clinics
Diagnostic centers
By Geography:
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Competitive Landscape
Roche, Abbott Laboratories Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., GE HealthCare, Beckman Coulter, Inc., FUJIREBIO is an H.U. Group company, Laboratory Corporation of America Holdings, Bayer AG, Abcam plc, Lomina AG, LynxDx, and AdvaCare Pharma are the leading players in the prostate-specific antigen test market, driving innovation and competitive growth. These companies focus on developing advanced, highly sensitive assays to improve early detection and monitoring of prostate cancer. Strategic collaborations, mergers, and partnerships enhance their distribution networks and expand regional presence. Continuous investment in research and development supports the launch of technologically advanced solutions, including automated and point-of-care testing platforms. Companies also prioritize regulatory compliance and quality certifications to strengthen market credibility. Rising awareness of early cancer detection, coupled with competitive pricing strategies, enables these firms to maintain a strong foothold. Overall, the market is characterized by technological innovation, strategic alliances, and increasing adoption across hospitals, specialty clinics, and diagnostic centers.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In 2025, Roche confirmed its strategy to grow its diagnostics division through advancements in pathology solutions and blood screening tests, alongside its core PSA offerings.
In 2025, Thermo Fisher Scientific launched the Orbitrap Astral Zoom mass spectrometer at ASMS 2025, which provides enhanced sensitivity and speed for analyzing proteins and discovering clinical biomarkers, significantly accelerating disease research like that for cancer
In 2023, LynxDx Commercialized its MyProstateScore 2.0 urine-based prostate cancer screening test.
Report Coverage
The research report offers an in-depth analysis based on Type, Application, End-Use and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The market will expand with rising global prostate cancer prevalence.
Early detection awareness campaigns will drive wider adoption of PSA testing.
Technological advancements will improve test accuracy and reduce false positives.
Point-of-care diagnostics will see increased demand in both urban and rural areas.
Personalized medicine will integrate PSA testing with genetic and molecular profiling.
Emerging markets will experience rapid growth due to healthcare investments.
Hospitals will remain the largest end users, supported by advanced infrastructure.
Reimbursement policies will continue to support adoption in developed regions.
Partnerships between diagnostic firms and healthcare providers will enhance market reach.
Growing male aging populations will sustain long-term demand for PSA testing.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
3. Executive Summary
4. Introduction
4.1. Overview
4.2. Key Industry Trends
5. Global Prostate Specific Antigen Test Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast
12. Porters Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes
13. Price Analysis
14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Roche
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. Abbott Laboratories Inc.
14.3.3. Thermo Fisher Scientific
14.3.4. Bio-Rad Laboratories, Inc.
14.3.5. GE HealthCare
14.3.6. Beckman Coulter, Inc.
14.3.7. FUJIREBIO (H.U. Group company)
14.3.8. Laboratory Corporation of America Holdings
14.3.9. Bayer AG
14.3.10. Abcam plc
14.3.11. Lomina AG
14.3.12. LynxDx
14.3.13. AdvaCare Pharma
15. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Prostrate Specific Antigen Test Market, and what is its projected size in 2032?
The market size was USD 4.63 Billion in 2024 and is projected to reach USD 11.23 Billion by 2032.
At what Compound Annual Growth Rate is the Prostrate Specific Antigen Test Market projected to grow between 2025 and 2032?
The market is projected to grow at a CAGR of 11.7% during the forecast period.
Which Prostrate Specific Antigen Test Market segment held the largest share in 2024?
Preliminary tests dominated the market segment in 2024 with over 58% share.
What are the primary factors fueling the growth of the Prostrate Specific Antigen Test Market?
Rising prostate cancer prevalence, technological advancements, and government-led screening initiatives drive growth.
Who are the leading companies in the Prostrate Specific Antigen Test Market?
Key players include Roche, Abbott Laboratories Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, and GE HealthCare.
Which region commanded the largest share of the Prostrate Specific Antigen Test Market in 2024?
North America led the market with a 38% share in 2024.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The sphygmomanometer market size was valued at USD 3.38 billion in 2024 and is anticipated to reach USD 6.54 billion by 2032, at a CAGR of 8.6 % during the forecast period.
The Orthopedic Devices Market size was valued at USD 51.45 billion in 2024 and is anticipated to reach USD 73.17 billion by 2032, at a CAGR of 4.5% during the forecast period.
France Sleep Apnea Devices Market size was valued at USD 250.70 million in 2018, reached USD 377.95 million in 2024, and is anticipated to reach USD 650.25 million by 2032, at a CAGR of 6.53% during the forecast period.
The temperature modulation devices market size was valued at USD 3.05 billion in 2024 and is anticipated to reach USD 5.06 billion by 2032, at a CAGR of 6.5 % during the forecast period.
The tendon repair market size was valued at USD 2.56 billion in 2024 and is anticipated to reach USD 5.11 billion by 2032, at a CAGR of 9 % during the forecast period.
The Thyroid Cancer Diagnostics Market size was valued at USD 2.86 billion in 2024 and is anticipated to reach USD 4.2 billion by 2032, at a CAGR of 4.9 % during the forecast period.
Refurbished MRI Systems Market size was valued at USD 799.03 million in 2024 and is anticipated to reach USD 1216.99 million by 2032, at a CAGR of 5.4% during the forecast period.
Germany Sleep Apnea Devices Market size was valued at USD 226.51 million in 2018, reached USD 348.72 million in 2024, and is anticipated to reach USD 619.78 million by 2032, growing at a CAGR of 6.94% during the forecast period.
Refurbished Medical Imaging Devices Market size was valued USD 16.55 billion in 2024 and is anticipated to reach USD 28.87 billion by 2032, at a CAGR of 7.2% during the forecast period.
The Prosthetic Heart Valves market size was valued at USD 9.5 billion in 2024 and is anticipated to reach USD 21.43 billion by 2032, at a CAGR of 10.7% during the forecast period.
Rehabilitation Equipment Market size was valued USD 20.07 billion in 2024 and is anticipated to reach USD 29.89 billion by 2032, at a CAGR of 5.1% during the forecast period.
The global X-ray detectors market was valued at USD 4 billion in 2024 and is projected to reach USD 5.61 billion by 2032, growing at a CAGR of 5.88% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
